News stories about Viewray (NASDAQ:VRAY) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Viewray earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.2411639498532 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Viewray (VRAY) opened at $9.18 on Friday. The company has a market capitalization of $617.88, a price-to-earnings ratio of -8.12 and a beta of 0.11. The company has a quick ratio of 1.20, a current ratio of 1.59 and a debt-to-equity ratio of -1.67. Viewray has a twelve month low of $3.01 and a twelve month high of $10.39.
Viewray (NASDAQ:VRAY) last posted its earnings results on Monday, November 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The company had revenue of $12.20 million during the quarter, compared to analysts’ expectations of $18.63 million. The business’s revenue for the quarter was up 2950.0% on a year-over-year basis. equities analysts expect that Viewray will post -0.93 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/12/23/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-viewray-vray-stock-price.html.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.